2024

1. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

   Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593

2. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

   The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

3. Correction to: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review (Blood Cancer Journal, (2024), 14, 1, (24), 10.1038/s41408-023-00966-9)

   Blood Cancer Journal

4. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

   New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313

5. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

   Blood Cancer Journal, Vol. 14, Núm. 1